EcoDrugPlus

Proteasome 20s Subunit Alpha 6b

Ensembl ID : ENSOMEG00000014251
Gene Symbol: PSMA6B
1 Cross references
278 Possible Orthologues:

Proteasome 20s Subunit Alpha 8

Ensembl ID : ENSOMEG00000004187
Gene Symbol: PSMA8
3 Cross references
182 Possible Orthologues:

Proteasome 20s Subunit Beta 1

Ensembl ID : ENSOMEG00000005450
Gene Symbol: PSMB1
3 Cross references
217 Possible Orthologues:

Proteasome 20s Subunit Beta 2

Ensembl ID : ENSOMEG00000006246
Gene Symbol: PSMB2
3 Cross references
219 Possible Orthologues:

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSOMEG00000019384
Gene Symbol: PSMB3
3 Cross references
260 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSOMEG00000010461
Gene Symbol: PSMB4
1 Cross references
214 Possible Orthologues:

Proteasome 20s Subunit Beta 6

Ensembl ID : ENSOMEG00000007303
Gene Symbol: PSMB6
3 Cross references
230 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSOMEG00000017931
Gene Symbol: PSMB7
3 Cross references
216 Possible Orthologues:

Proteasome 20s Subunit Beta 9a

Ensembl ID : ENSOMEG00000020353
Gene Symbol: PSMB9A
1 Cross references
182 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4

Ensembl ID : ENSOMEG00000005853
Gene Symbol: PSMD4
3 Cross references
225 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4b

Ensembl ID : ENSOMEG00000006340
Gene Symbol: PSMD4B
1 Cross references
220 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSOMEG00000014141
Gene Symbol: PSMC1
3 Cross references
281 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).